A Study To Evaluate Safety And Efficacy Of Ocrelizumab In Comparison With Fingolimod In Children And Adolescents With Relapsing-Remitting Multiple Sclerosis

Inclusion Criteria:

Body weight ≥ 50 kg
Diagnosis of RRMS in accordance with the International Pediatric Multiple Sclerosis Study Group (IPMSSG) criteria for pediatric MS, Version 2012, or McDonald criteria 2017
EDSS at screening: 0-5.5, inclusive
Neurologic stability for ≥ 30 days prior to screening, and between screening and Day 1
At least one MS relapse during the previous year or two MS relapses in the previous 2 years or evidence of at least one Gd enhancing lesion on MRI within 6 months

Exclusion Criteria:

Known presence or suspicion of other neurologic disorders that may mimic MS
Significant uncontrolled somatic diseases, known active infection or any other significant condition that may preclude patient from participating in the study
Patient with severe cardiac disease or significant findings on the screening ECG